Beta Bionics Posts Record-Breaking Q1 2026 Earnings with 57% Year-Over-Year Revenue Growth
Beta Bionics, a pioneering medical device company, has announced its most impressive quarterly earnings to date. In the first quarter of 2026, the company achieved $27.6 million in net sales, representing a staggering 57% year-over-year growth.
According to Sean Saint, Chief Executive Officer, this remarkable performance was driven primarily by the growth in new patient starts and the increasing number of users accessing their monthly supplies for the iLet through the pharmacy channel. Notably, the percentage of new patient starts that were reimbursed through the pharmacy channel rose to a high 30s percentage, compared to a low 30s percentage in Q4 and a mere low 20s percentage in Q1 2025.
The company's gross margin also witnessed an exceptional expansion of over 860 basis points year-over-year, reaching 59.5%. This remarkable achievement underscores the efficacy of the pharmacy business model and Beta Bionics' ability to drive leverage and manufacturing costs as they scale.
Stephen Feider, Chief Financial Officer, further elaborated on the company's Q1 performance, stating that revenue growth was primarily fueled by new patient starts and recurring revenue generated from their expanding pharmacy installed base. He also highlighted the importance of the pharmacy strategy in delivering strong financial results for the business.
Notably, despite a decline in new patient starts compared to Q4 2025, Beta Bionics demonstrated a high level of retention among patients utilizing the product. This is a testament to the company's commitment to providing life-changing solutions to the diabetes community and their relentless pursuit of excellence.
The record-breaking earnings announcement has sent a strong message about the company's growth prospects and ability to execute on its strategic initiatives. As Beta Bionics continues to advance its Mint patch pump program, bi-hormonal program, and expand pharmacy channel access, investors and stakeholders alike are eagerly awaiting further updates on this promising medical device company.
With a proven track record of innovation and execution, Beta Bionics is well-positioned for continued success in the years to come. As the company continues to drive adoption of the iLet and push the boundaries of what is possible in diabetes management, one thing is certain – the future looks bright for this pioneering medical device company.
As Beta Bionics embarks on its next phase of growth, it is clear that the company's commitment to innovation, execution, and customer satisfaction will remain at the forefront of their strategy. With a strong foundation in place, investors and stakeholders alike are likely to see continued success from this exciting medical device company.
"
